The GOG Foundation, Inc (GOG) Letter of
Authorization Executed
Retention of IQVIA as global contract
research organization for Phase 3 trial
TSX Venture: QPT
EDMONTON, Jan. 25, 2019 /CNW/ - Quest PharmaTech Inc.
(TSX-V: QPT) ("Quest" or the "Company"), a biopharmaceutical
company developing and commercializing products to improve the
quality of life, today announced that its subsidiary, OncoQuest
Inc., has retained the services of IQVIA, a company formed through
the merger of IMS Health and Quintiles, to manage OncoQuest's
planned Phase 3 clinical study in frontline ovarian cancer with the
company's lead product candidate, oregovomab, an anti-CA-125
antibody. OncoQuest will collaborate with IQVIA, a leading global
provider of advanced analytics, technology solutions and contract
research services to the life sciences industry, to provide
oversight of the day-to-day study execution activities.
OncoQuest has also signed a Letter of Authorization with The GOG
Foundation, Inc. (GOG-F) to provide consultation on regulatory
strategy, protocol design and additional aspects of the Phase 3
study, and to coordinate participation of GOG-affiliated study
sites.
The planned Phase 3 study is expected to enroll over 500
patients with newly diagnosed, advanced ovarian cancer globally.
The primary endpoint will be to evaluate progression-free survival
of patients treated with oregovomab plus a standard-of-care
chemotherapy combination, carboplatin and paclitaxel, compared to
the chemotherapy alone. Patients will also undergo tumor debulking
surgery either before or halfway through the treatment. This
Phase 3 study is based on a Phase 2 study with a similar design
where promising results were noted [NCT01616303].
"We are delighted to have the services and support of two
well-respected and internationally recognized organizations to
assist and guide our pivotal Phase 3 study of oregovomab," said Dr.
Eliel Bayever, M.B.B.Ch, M.R.C.P.,
Chief Medical Officer of OncoQuest, "We have chosen these two
partners based on their extensive experience in global cancer
studies, and, specifically with GOG-F, their focus on gynecologic
cancers."
"I am pleased that GOG-F is working with OncoQuest on this very
exciting trial to investigate whether the combination of oregovomab
together with the standard-of-care chemotherapeutic regimen can
demonstrate an improvement in progression-free survival in women
with newly diagnosed advanced ovarian cancer," said Bradley J. Monk, M.D., FACS, FACOG, Co‐Director
of GOG Partners, Arizona Oncology (US Oncology Network), Professor,
Gynecologic Oncology at University of
Arizona, and Creighton
University, Medical Director of US Oncology Research
Gynecology program in Phoenix,
Arizona.
About OncoQuest
OncoQuest is a subsidiary of Quest PharmaTech Inc. (TSXV-QPT)
("Quest") and is a private biopharmaceutical company focused on the
development and commercialization of immunotherapies for cancer.
OncoQuest's technology platform includes a portfolio of tumor
antigen specific monoclonal immunoglobulins including CA-125, MUC1,
PSA and Her2/neu. The company is exploring the therapeutic
potential of these antibodies in combination with other immune
modulating drugs or drug combinations to enhance tumor specific
immunity and clinical outcomes.
OncoQuest's lead product candidate is oregovomab, an anti-CA-125
antibody, for the treatment of ovarian cancer that has completed a
Phase 2 frontline randomized controlled study. In addition,
oregovomab is currently being studied in multiple Phase 2 clinical
trials in the relapsed recurrent ovarian cancer setting as well.
OncoQuest's anti-MUC1 antibody program has already undergone a
Phase 1 clinical trial in breast cancer patients, and its
development is being led by OncoVent Co. Ltd., OncoQuest's joint
venture partner that has licensed the rights of our
immunotherapeutic antibodies in the territory of Greater China. OncoQuest's next-generation
monoclonal antibodies are based on immunoglobulin E licensed from
UCLA, Stanford
University and Advanced Immune Therapeutics, Inc. These
antigen-specific monoclonal IgE antibodies are currently in
preclinical development. To learn more, visit
www.oncoquestinc.com .
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced
analytics, technology solutions and contract research services to
the life sciences industry. Formed through the merger of IMS Health
and Quintiles, IQVIA applies human data science — leveraging the
analytic rigor and clarity of data science to the ever-expanding
scope of human science — to enable companies to reimagine and
develop new approaches to clinical development and
commercialization, speed innovation and accelerate improvements in
healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers
unique and actionable insights at the intersection of large-scale
analytics, transformative technology and extensive domain
expertise, as well as execution capabilities. With more than 58,000
employees, IQVIA conducts operations in more than 100 countries. To
learn more, visit www.iqvia.com
About the GOG Foundation, Inc. (GOG-F)
The GOG Foundation, Inc. (GOG Foundation) is an independent
international non-profit organization with the purpose of promoting
excellence in the quality and integrity of clinical and basic
scientific research in the field of gynecologic malignancies,
including cancers that arise from the ovaries, uterus, cervix,
vagina, and vulva. The mission of the GOG Foundation is to
conduct clinical and translational research that positively impacts
women through the prevention and treatment of
gynecologic malignancies. To learn more, visit
www.gog.org
About Quest PharmaTech Inc.
Quest PharmaTech Inc is a
publicly traded, Canadian based biopharmaceutical company (QPT:
TSX-V) developing products to improve the quality of life. The
Company through its subsidiary, OncoQuest and its Chinese joint
venture, OncoVent, is developing antibody-based immunotherapeutic
products for cancer. Quest has an
ownership interest in Bioceltran which is focused on SP Technology™
for transdermal delivery of drugs and photosensitizers for
pharmaceutical and cosmetic purposes. Quest through its subsidiary, Madenco BioSciences,
is developing pharmaceutical products for dermatology and wound
healing applications. Quest,
through its ownership interest in OncoCare Therapeutics, is
developing an antibody licensed from University of Nebraska, AR 9.6 mAb against
truncated O-glycan on MUC16, for targeted cancer therapy
applications. To learn more, visit
www.questpharmatech.com
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE Quest PharmaTech Inc.